COMMUNIQUÉS West-GlobeNewswire
-
CorMedix Therapeutics Announces Positive Data From Ongoing Real World Evidence Study of DefenCath
18/12/2025 -
First Patient Dosed in SAB BIO’s SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D
18/12/2025 -
Beacon Therapeutics to Present at the 44th Annual JP Morgan Healthcare Conference
18/12/2025 -
Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference
18/12/2025 -
Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus
18/12/2025 -
Numab Therapeutics Achieves Milestone in Second Collaboration Project with Boehringer Ingelheim
18/12/2025 -
Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease
18/12/2025 -
Sienna Announces Completion of $250 Million Offering of 3.524% Series F Senior Unsecured Debentures
18/12/2025 -
Intelligent Bio Solutions Announces Strategic Partnership with Vlepis, Provider of Advanced Sensing and Wearable Patch Technologies, to Drive Innovation in Non-Invasive Screening and Consumer Health Monitoring
18/12/2025 -
NetraMark Delivers Transformational Quarter Of Execution
18/12/2025 -
Autonomix Medical, Inc. Announces Abstract Selected for Poster Presentation at the 2026 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
18/12/2025 -
Mangoceuticals, Inc. Announces $2.5 Million Registered Direct and Private Placements Priced at the Market Under Nasdaq Rules
18/12/2025 -
Akari Therapeutics Releases Virtual Investor “What This Means” Segment
18/12/2025 -
Treace Medical Secures Up to $175 Million in Debt Financing
18/12/2025 -
Aprea Therapeutics CEO Issues Letter to Shareholders Highlighting Pipeline Progress in 2025 and Outlook for 2026
18/12/2025 -
Picard Medical Marks Public Company Milestone by Ringing the NYSE Opening Bell
18/12/2025 -
Biodexa Announces Pricing of $10 Million Public Offering
18/12/2025 -
Biofrontera Inc. Completes Transfer of Ameluz® and RhodoLED® FDA approval and Associated Intellectual Property Portfolio
18/12/2025 -
Actuate Therapeutics Phase 2 Metastatic Pancreatic Cancer Data Selected for Oral and Poster Presentation at ASCO GI 2026
18/12/2025
Pages